Market share of Novo Nordisk’s Tresiba grew twice more in 2nd quarter
The market share of a Novo Nordisk Pharma Korea’s next-generation basal insulin, Tresiba Flextouch Inj(generic name: insulin degludec), was increased by double in the 2nd quarter compared to the one of the 1st quarter in 2016.
According to data of IMS, a pharmaceutical market research company, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
